drugset / Trial / NCT06565026
CS-206 in Patients With Sickle Cell Disease
Phase 0
Recruiting
5 enrolled
CorrectSequence Therapeutics Co., Ltd
First Affiliated Hospital of Guangxi Medical University · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this open label, single-arm clinical study is to learn about the safety and efficacy of CS-101 injection in treating sickle cell disease.
Timeline
- Start
- 2024-09-02
- Primary completion
- 2026-12-31
- Completion
- 2027-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CS-206 | Cell therapy | — | — |